

AMENDMENT

IN THE CLAIMS

Please amend claims 1, 8, 11, and 15 without any prejudice or disclaimer to the subject matter expressed therein as indicated in the complete listing of all claims in the application set forth below.

Claim 1. (Currently Amended) An orally efficacious and prolonged duration of action inclusion complex, consisting essentially of an opioid peptide of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide and a cyclodextrin derivative, wherein said inclusion complex is formulated for oral administration effective when administered orally to a patient in need thereof, and wherein the molar ratio between said L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide and said cyclodextrin derivative is 1:5 to 2:1, and wherein said inclusion complex does not contain an acid component.

Claim 2. (Previously Presented) Inclusion complex as claimed in claim 1, wherein the cyclodextrin derivative is selected from beta cyclodextrin, hydroxypropyl-beta cyclodextrin, dimethyl-beta cyclodextrin, and hydroxyethyl-beta-cyclodextrin.

Claim 3. (Previously Presented) Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with beta-cyclodextrin.

Claim 4. (Previously Presented) Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxyethyl beta-cyclodextrin.

Claim 5. (Original) Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with hydroxypropyl beta-cyclodextrin.

Claim 6. (Previously Presented) Inclusion complex as claimed in claim 1 comprising L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with dimethyl beta-cyclodextrin.

Claim 7. (Canceled)

Claim 8. (Currently Amended) Pharmaceutical compositions consisting essentially of a therapeutically effective amount of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with the cyclodextrin derivative as claimed in claim 1 having improved analgesic activity with longer duration of action as compared with the free peptide, wherein said pharmaceutical compositions are formulated for oral administration.

Claim 9. (Original) Pharmaceutical composition as claimed in claim 8 having potential for clinical application as an analgesic.

Claim 10. (Canceled)

Claim 11. (Currently Amended) A method for the treatment of acute inflammations and for alleviating pain comprising the step of oral administration of a pharmaceutical composition containing the inclusion complex as claimed in claim 1 to a patient in need thereof.

Claims 12-13. (Canceled)

Claim 14. (Previously Presented) A method as claimed in claim 11 for the treatment of acute inflammations and for alleviating pain, which comprises an oral administration of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with said cyclodextrin derivative.

Claim 15. (Currently Amended) A method for the treatment of acute inflammations and for alleviating pain, which comprises a ~~topical application~~ oral administration of inclusion complex of L-Tyrosyl-D-alanyl-glycyl-N-methylphenylalanyl-glycyl-isopropylamide with the cyclodextrin derivative as claimed in claim 1.